H.R. 8205In committeeHealth care
Bill would extend ALS research grant law through 2031
Data as of July 23, 2026
HR 8205 extends ALS research grant funding authority from 2026 to 2031 and adds FDA oversight steps.AI-decoded45-second read · 4 questions answered below
Decoded
AI-decodedWhat does this do?
This bill extends the Accelerating Access to Critical Therapies for ALS Act, pushing its expiration from 2026 to 2031 so grant programs for ALS research can continue. It adds requirements for the FDA to check clinical trial progress, including interim data, when companies renew grants, and clarifies that "phase 3" trials include combined phase 2/3 and planned-but-not-yet-enrolling trials. It also requires an updated FDA action plan within a year and a GAO review within four years.
Who does it affect?
The bill affects ALS patients and families, pharmaceutical and biotech companies developing ALS treatments, and researchers using federal grants. The FDA gains added reporting and oversight duties.
Why does it matter?
The extension keeps existing grant funding authority active rather than letting it lapse in 2026, while adding new FDA data-sharing and reporting requirements that increase oversight of grant recipients.
Where does it stand?
- Introduced
- House committee — You are here
- House vote
- Senate
- President's desk
Right now: a House committee is reviewing it. If the Senate changes it, it goes back to the House before reaching the President.
AI-drafted summary. Verify it against the official text before you act on it.
Make the call
Three steps: where you stand, your script, the call.
See how a call works
Official title
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
- Introduced:
- April 6, 2026
- Latest action:
- July 22, 2026
Motion to reconsider laid on the table Agreed to without objection.
Read the official bill on Congress.gov